MedTrace Logo

Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)

NCT01165710 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10179

Last updated 2017-01-24

No results posted yet for this study

Summary

The ORBIT-AF registry will be a multicenter, prospective outpatient disease registry to identify "real world" treatment patterns of atrial fibrillation. The registry will describe this patient population with regards to demographics, clinical factors, risk stratification, and geographic regions. In particular, attention will be focused on the utilization, effectiveness, and safety of antithrombotic therapies in the prevention of stroke. The registry is designed to identify reasons and risk factors for non-receipt of anticoagulation (AC) therapy, as well as reasons why AF patients who are prescribed AC therapy do not take them.

Conditions

Interventions

OTHER

Patients with Atrial Fibrillation (AF)

Treatment patterns of AF according to patient demographics, clinical factors, risk stratification, and geographic regions.

Sponsors & Collaborators

  • Duke Clinical Research Institute

    collaborator OTHER

  • Bayer

    collaborator INDUSTRY

  • Janssen Scientific Affairs, LLC

    lead INDUSTRY

Principal Investigators

  • Janssen Scientific Affairs, LLC Clinical Trial · Janssen Scientific Affairs, LLC

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2014-11-30
Completion
2014-12-31

Countries

  • United States
  • Puerto Rico

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01165710 on ClinicalTrials.gov